Inhibikase Therapeutics (IKT) Current Assets (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Current Assets data on file, last reported at $172.2 million in Q1 2026.

• On a quarterly basis, Current Assets rose 82.85% year-over-year to $172.2 million in Q1 2026; TTM through Mar 2026 was $172.2 million, a 82.85% increase from a year earlier, with the FY2025 full-year figure at $180.1 million, up 82.94% from the prior year.
• Current Assets for Q1 2026 stood at $172.2 million, down from $180.1 million in the prior quarter.
• Over the last five years, Current Assets for IKT reached as high as $180.1 million in Q4 2025 and fell as low as $4.2 million in Q3 2024.
• Historically, Current Assets has averaged $56.5 million across 5 years, with a median of $27.8 million in 2022.
• Across the five-year window, Current Assets plunged 76.13% in 2024 and jumped 1774.34% in 2025, its largest moves.
• Year by year, Current Assets stood at $24.4 million in 2022, then tumbled by 41.69% to $14.2 million in 2023, then surged by 592.78% to $98.5 million in 2024, then soared by 82.94% to $180.1 million in 2025, then decreased by 4.4% to $172.2 million in 2026.
• Per Business Quant data, the three most recent Current Assets figures were $172.2 million in Q1 2026, $180.1 million in Q4 2025, and $78.5 million in Q3 2025.